Related Experiment Video
Updated: Jun 9, 2026
16:40
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Drug-implantable cardioverter-defibrillator interactions
Roger Beadle1, Lynne Williams, Hoong Sern Lim
1School of Medicine and Dentistry, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, Scotland AB25 2ZD, UK. rogerbeadle@hotmail.com
Expert Review of Cardiovascular Therapy
|September 11, 2010
Summary
Antiarrhythmic drugs and implantable cardioverter defibrillators (ICDs) manage arrhythmias but can interact. This article summarizes potential drug-device interactions, especially in complex patients.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Background:
- Antiarrhythmic drugs are frequently co-prescribed with implantable cardioverter defibrillators (ICDs) for treating ventricular and supraventricular arrhythmias.
- The use of ICDs is expanding, including in patients with multiple comorbidities, increasing the likelihood of drug-device interactions.
Purpose of the Study:
- To summarize potential drug-device interactions between antiarrhythmic drugs and ICDs.
- To highlight the clinical significance of these interactions in patient management.
Main Methods:
- Literature review of studies on antiarrhythmic drug and ICD interactions.
- Analysis of direct and indirect mechanisms of drug-device interaction.
Main Results:
- Antiarrhythmic drugs can affect ICD sensing, pacing, and defibrillation thresholds.
- Drug-induced proarrhythmia can lead to inappropriate ICD shocks.
- Comorbidities can exacerbate drug-device interactions.
Conclusions:
- Understanding potential drug-device interactions is crucial for optimizing therapy in patients with arrhythmias treated with ICDs.
- Careful medication management and device monitoring are essential to minimize adverse events.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...